Regenxbio (RGNX) Capital Leases (2018)

Regenxbio (RGNX) recorded quarterly Capital Leases of $5.9 million in Q4 2018.

Regenxbio (RGNX) Capital Leases (2018) Analysis & Trends

Regenxbio's Capital Leases history runs 1 years deep, the most recent figure standing at $5.9 million for Q4 2018.

In Q4 2018, Capital Leases changed N/A year-over-year to $5.9 million; the TTM figure through Dec 2018 stood at $5.9 million (changed N/A YoY), while the FY2018 annual figure was $5.9 million, changed N/A from the prior year.
Capital Leases was $5.9 million for Q4 2018 at Regenxbio.
In the past five years, Capital Leases ranged from a high of $5.9 million in Q4 2018 to a low of $5.9 million in Q4 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Regenxbio	315.11 Mn	85.04 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2018	5.85 Mn